文献速递白血病

维奈克拉联合低剂量阿糖胞苷治疗初治急性髓系白血病:Ib/II期研究结果

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
PubMed 文献 · J Clin Oncol · 2019-03-20

国际Ib/II期研究评估维奈克拉联合低剂量阿糖胞苷(LDAC)治疗≥60岁不适合强化化疗的初治AML患者,82例接受II期推荐剂量治疗。54%达完全缓解/完全缓解伴血细胞计数不完全恢复,中位总生存10.1个月,中位缓解持续时间8.1个月。结论认为该方案安全性可控,可产生快速持久缓解。

要点

  • 维奈克拉600 mg每日口服联合LDAC 20 mg/m2皮下注射第1-10天,28天为一周期。
  • 54%患者达完全缓解/完全缓解伴血细胞计数不完全恢复,中位至首次缓解1.4个月。
  • 中位总生存10.1个月,中位缓解持续时间8.1个月,30天早期死亡率6%。

核心结论

  • 维奈克拉联合LDAC安全性可控,在不适合强化化疗的老年AML患者中产生快速且持久的缓解。

研究设计与样本

  • 国际Ib/II期研究,纳入≥60岁不适合强化化疗的初治AML成人患者,82例接受II期推荐剂量治疗。

主要发现

  • 中位年龄74岁(范围63至90岁),49%为继发性AML,29%既往接受去甲基化药物治疗,32%具有不良风险细胞遗传学特征。
  • 常见≥3级不良事件为发热性中性粒细胞减少(42%)、血小板减少(38%)和白细胞计数降低(34%)。
  • 54%达完全缓解/完全缓解伴血细胞计数不完全恢复,中位至首次缓解1.4个月。
  • 中位总生存10.1个月(95%CI 5.7至14.2),中位缓解持续时间8.1个月(95%CI 5.3至14.9个月)。
  • 无既往去甲基化药物治疗患者中,62%达完全缓解/完全缓解伴血细胞计数不完全恢复,中位缓解持续时间14.8个月(95%CI 5.5个月至未达到),中位总生存13.5个月(95%CI 7.0至18.4个月)。

关键数值与推荐

  • II期推荐剂量:维奈克拉600 mg每日口服,28天为一周期,联合LDAC 20 mg/m2每日皮下注射第1至10天。
  • 30天早期死亡率为6%。

临床怎么用

  • 原文结论认为维奈克拉联合LDAC是不适合强化化疗的老年AML患者有吸引力且新颖的治疗选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Effective treatment options are limited for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study evaluated the safety and preliminary efficacy of venetoclax, a selective B-cell leukemia/lymphoma-2 inhibitor, together with low-dose cytarabine (LDAC) in older adults with AML. PATIENTS AND METHODS: Adults 60 years or older with previously untreated AML ineligible for intensive chemotherapy were enrolled. Prior treatment of myelodysplastic syndrome, including hypomethylating agents (HMA), was permitted. Eighty-two patients were treated at the recommended phase II dose: venetoclax 600 mg per day orally in 28-day cycles, with LDAC (20 mg/m2 per day) administered subcutaneously on days 1 to 10. Key end points were tolerability, safety, response rates, duration of response (DOR), and overall survival (OS). RESULTS: Median age was 74 years (range, 63 to 90 years), 49% had secondary AML, 29% had prior HMA treatment, and 32% had poor-risk cytogenetic features. Common grade 3 or greater adverse events were febrile neutropenia (42%), thrombocytopenia (38%), and WBC count decreased (34%). Early (30-day) mortality was 6%. Fifty-four percent achieved complete remission (CR)/CR with incomplete blood count recovery (median time to first response, 1.4 months). The median OS was 10.1 months (95% CI, 5.7 to 14.2), and median DOR was 8.1 months (95% CI, 5.3 to 14.9 months). Among patients without prior HMA exposure, CR/CR with incomplete blood count recovery was achieved in 62%, median DOR was 14.8 months (95% CI, 5.5 months to not reached), and median OS was 13.5 months (95% CI, 7.0 to 18.4 months). CONCLUSION: Venetoclax plus LDAC has a manageable safety profile, producing rapid and durable remissions in older adults with AML ineligible for intensive chemotherapy. High remission rate and low early mortality combined with rapid and durable remission make venetoclax and LDAC an attractive and novel treatment for older adults not suitable for intensive chemotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wei AH, Strickland SA, Hou JZ, et al. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. J Clin Oncol. 2019. PMID: 30892988. doi:10.1200/JCO.18.01600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。